在阿尔茨海默病转基因小鼠模型中,疫苗接种引起促炎细胞因子水平变化,作为认知改善的早期假定生物标志物。
Vaccination induced changes in pro-inflammatory cytokine levels as an early putative biomarker for cognitive improvement in a transgenic mouse model for Alzheimer disease.
作者信息
Lin Xiaoyang, Bai Ge, Lin Linda, Wu Hengyi, Cai Jianfeng, Ugen Kenneth E, Cao Chuanhai
机构信息
a Department of Pharmacuetical Sciences College of Pharmacy; University of South Florida; Tampa, FL USA.
出版信息
Hum Vaccin Immunother. 2014;10(7):2024-31. doi: 10.4161/hv.28735.
Several pieces of experimental evidence suggest that administration of anti-β amyloid (Aβ) vaccines, passive anti-Aβ antibodies or anti-inflammatory drugs can reduce Aβ deposition as well as associated cognitive/behavioral deficits in an Alzheimer disease (AD) transgenic (Tg) mouse model and, as such, may have some efficacy in human AD patients as well. In the investigation reported here an Aβ 1-42 peptide vaccine was administered to 16-month old APP+PS1 transgenic (Tg) mice in which Aβ deposition, cognitive memory deficits as well as levels of several pro-inflammatory cytokines were measured in response to the vaccination regimen. After vaccination, the anti-Aβ 1-42 antibody-producing mice demonstrated a significant reduction in the sera levels of 4 pro-inflammatory cytokines (TNF-α, IL-6, IL-1 α, and IL-12). Importantly, reductions in the cytokine levels of TNF-α and IL-6 were correlated with cognitive/behavioral improvement in the Tg mice. However, no differences in cerebral Aβ deposition in these mice were noted among the different control and experimental groups, i.e., Aβ 1-42 peptide vaccinated, control peptide vaccinated, or non-vaccinated mice. However, decreased levels of pro-inflammatory cytokines as well as improved cognitive performance were noted in mice vaccinated with the control peptide as well as those immunized with the Aβ 1-42 peptide. These findings suggest that reduction in pro-inflammatory cytokine levels in these mice may be utilized as an early biomarker for vaccination/treatment induced amelioration of cognitive deficits and are independent of Aβ deposition and, interestingly, antigen specific Aβ 1-42 vaccination. Since cytokine changes are typically related to T cell activation, the results imply that T cell regulation may have an important role in vaccination or other immunotherapeutic strategies in an AD mouse model and potentially in AD patients. Overall, these cytokine changes may serve as a predictive marker for AD development and progression as well as having potential therapeutic implications.
多项实验证据表明,给予抗β淀粉样蛋白(Aβ)疫苗、被动抗Aβ抗体或抗炎药物可减少阿尔茨海默病(AD)转基因(Tg)小鼠模型中的Aβ沉积以及相关的认知/行为缺陷,因此,对人类AD患者可能也有一定疗效。在本文报道的研究中,将Aβ 1-42肽疫苗给予16月龄的APP+PS1转基因(Tg)小鼠,检测接种疫苗方案后小鼠的Aβ沉积、认知记忆缺陷以及几种促炎细胞因子的水平。接种疫苗后,产生抗Aβ 1-42抗体的小鼠血清中4种促炎细胞因子(TNF-α、IL-6、IL-1α和IL-12)水平显著降低。重要 的是,TNF-α和IL-6细胞因子水平的降低与Tg小鼠的认知/行为改善相关。然而,在不同的对照组和实验组,即接种Aβ 1-42肽疫苗、接种对照肽疫苗或未接种疫苗的小鼠之间,未发现这些小鼠脑内Aβ沉积有差异。不过,接种对照肽疫苗的小鼠和接种Aβ 1-42肽疫苗的小鼠均出现促炎细胞因子水平降低以及认知能力改善。这些发现表明,这些小鼠促炎细胞因子水平的降低可作为疫苗接种/治疗诱导认知缺陷改善的早期生物标志物,且与Aβ沉积无关,有趣的是,也与抗原特异性Aβ 1-42疫苗接种无关。由于细胞因子变化通常与T细胞激活有关,结果表明T细胞调节在AD小鼠模型以及可能在AD患者的疫苗接种或其他免疫治疗策略中可能起重要作用。总体而言,这些细胞因子变化可作为AD发生发展的预测标志物,并具有潜在的治疗意义。
相似文献
Alzheimers Res Ther. 2018-11-20
Biochem Biophys Res Commun. 2010-8-1
引用本文的文献
Neurol Sci. 2025-3-20
Sultan Qaboos Univ Med J. 2015-8
本文引用的文献
J Am Med Dir Assoc. 2013-6-20
Proc Natl Acad Sci U S A. 2013-1-15
Acta Biochim Biophys Sin (Shanghai). 2012-8-16
Alzheimers Res Ther. 2012-5-23
J Immunoassay Immunochem. 2012-1
BMC Neurosci. 2008-2-18